Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma
Public ClinicalTrials.gov record NCT02371746. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center, Three-Stage, Open-Label, Prospective, Active-Comparator-Controlled Phase 2a Study of ENV515 (Travoprost) Intracameral Implant in Patients With Bilateral Ocular Hypertension or Early Primary Open-Angle Glaucoma
Study identification
- NCT ID
- NCT02371746
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Envisia Therapeutics
- Industry
- Enrollment
- 41 participants
Conditions and interventions
Conditions
Interventions
- ENV515-3 Travoprost XR Drug
- ENV515-1 Travoprost XR Drug
- ENV515-3-2 Travoprost XR Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2014
- Primary completion
- Feb 12, 2019
- Completion
- Feb 12, 2019
- Last update posted
- Oct 16, 2019
2015 – 2019
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Chandler | Arizona | 85225 | — |
| Not listed | Garden Grove | California | 92843 | — |
| Not listed | Inglewood | California | 90301 | — |
| Not listed | Redding | California | 96002 | — |
| Not listed | Morrow | Georgia | 30260 | — |
| Not listed | Indianapolis | Indiana | 46260 | — |
| Not listed | Chesterfield | Missouri | 63017 | — |
| Not listed | Kansas City | Missouri | 64133 | — |
| Not listed | Cincinnati | Ohio | 45242 | — |
| Not listed | Portland | Oregon | 97210 | — |
| Not listed | Sioux Falls | South Dakota | 57108 | — |
| Not listed | Austin | Texas | 78731 | — |
| Not listed | Houston | Texas | 77025 | — |
| Not listed | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02371746, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 16, 2019 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02371746 live on ClinicalTrials.gov.